Browsing Tag
Hoth Therapeutics
5 posts
Hoth Therapeutics stock jumps on HT-VA data, but can HOTH turn preclinical promise into a real metabolic pipeline?
Hoth Therapeutics says HT-VA reprogrammed liver fat metabolism and outperformed semaglutide on key markers. Read what this means for HOTH now.
Hoth Therapeutics (NASDAQ: HOTH) stakes claim on emerging oncodermatology space with dual patent filings for HT-001
Hoth Therapeutics files dual patents for HT-001 in oncology dermatology. Find out what this means for its IP strategy and cancer care positioning.
Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest
Hoth Therapeutics reports tumor suppression with no toxicity for HT-KIT. Learn how this biotech play could reshape cancer care and investor sentiment.
Hoth Therapeutics advances HT-001 as promising therapy for EGFR inhibitor-related skin toxicities
Hoth Therapeutics, Inc. has announced positive findings for HT-001 treatment, positioning it as a potential breakthrough therapy for…
Hoth Therapeutics shares explode 34% on what could be a life-saving cancer drug
In a significant breakthrough, Hoth Therapeutics Inc., a biopharmaceutical company focused on novel cancer treatments, saw its stock…